Comparative Pharmacology
Head-to-head clinical analysis: REVUFORJ versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVUFORJ versus XELJANZ.
REVUFORJ vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
Oral, 500 mg twice daily.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category C
Category C
JAK Inhibitor
JAK Inhibitor